niraparib
Selected indexed studies
- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. (Ann Oncol, 2024) [PMID:39284381]
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. (J Clin Oncol, 2023) [PMID:36952634]
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (N Engl J Med, 2019) [PMID:31562799]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. (2024) pubmed
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. (2023) pubmed
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (2019) pubmed
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. (2016) pubmed
- Niraparib. (2012) pubmed
- Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. (2023) pubmed
- Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. (2023) pubmed
- Lactate accumulation induces H4K12la to activate super-enhancer-driven RAD23A expression and promote niraparib resistance in ovarian cancer. (2025) pubmed
- Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial. (2025) pubmed
- Niraparib. (2006) pubmed